| Theme | Gastrointestinal Lymphoma -- Recent Advances in the Diagnosis and Management | |
|---|---|---|
| Title | H. pylori Eradication Therapy for Gastric MALT Lymphoma | |
| Publish Date | 2012/12 | |
| Author | Shoko Ono | Division of Endoscopy, Hokkaido University Hospital |
| Author | Mototsugu Kato | Division of Endoscopy, Hokkaido University Hospital |
| Author | Masahiro Asaka | Division of Endoscopy, Hokkaido University Hospital |
| [ Summary ] | Helicobacter pylori (H. pylori) plays a causative role in the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori leads to complete remission of the disease in 60 - 80 % of gastric MALT lymphoma cases. Although eradication therapy is not effective for H. pylori-negative cases, eradication is often recommended as the primary therapy. Predictors of resistance to eradication therapy are an absence of H. pylori, clinical stage, depth of lymphoma invasion, proximal location and t (11 ; 18)/API2-MALT1. Recently, there have been reports concerning long-term follow-ups to determine outcomes after eradication therapy. These reports have stated that the prognosis for gastric MALT lymphoma is excellent after this treatment. |
|